363 related articles for article (PubMed ID: 15189176)
1. Haemoglobin response to subcutaneous versus intravenous epoetin alfa administration in iron-replete haemodialysis patients.
Leikis MJ; Kent AB; Becker GJ; McMahon LP
Nephrology (Carlton); 2004 Jun; 9(3):153-60. PubMed ID: 15189176
[TBL] [Abstract][Full Text] [Related]
2. Effect of switching from subcutaneous to intravenous administration of epoetin-alpha in haemodialysis patients: results from a Swedish multicentre survey.
Linde T; Furuland H; Wikström B
Scand J Urol Nephrol; 2005; 39(4):329-33. PubMed ID: 16118109
[TBL] [Abstract][Full Text] [Related]
3. A comparison between once-weekly and twice- or thrice-weekly subcutaneous injection of epoetin alfa: results from a randomized controlled multicentre study.
Lee YK; Kim SG; Seo JW; Oh JE; Yoon JW; Koo JR; Kim HJ; Noh JW
Nephrol Dial Transplant; 2008 Oct; 23(10):3240-6. PubMed ID: 18469158
[TBL] [Abstract][Full Text] [Related]
4. Subcutaneous compared with intravenous epoetin treatment in patients on hemodialysis: one center study.
Malovrh M; Premru V
Ther Apher Dial; 2005 Jun; 9(3):233-6. PubMed ID: 15966996
[TBL] [Abstract][Full Text] [Related]
5. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
Pizzarelli F; David S; Sala P; Icardi A; Casani A
Am J Kidney Dis; 2006 Jun; 47(6):1027-35. PubMed ID: 16731298
[TBL] [Abstract][Full Text] [Related]
6. Efficacy prospective study of different frequencies of Epo administration by i.v. and s.c. routes in renal replacement therapy patients.
Messa P; Nicolini MA; Cesana B; Brezzi B; Zattera T; Magnasco A; Moroni G; Campise M
Nephrol Dial Transplant; 2006 Feb; 21(2):431-6. PubMed ID: 16249199
[TBL] [Abstract][Full Text] [Related]
7. Dose of epoetin alfa used in haemodialysis patients when switching from subcutaneous to intravenous administration.
Pussell BA; Walker R
Nephrology (Carlton); 2007 Apr; 12(2):120-5. PubMed ID: 17371332
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
[TBL] [Abstract][Full Text] [Related]
9. Results of the European Survey on Anaemia Management 2003 (ESAM 2003): current status of anaemia management in dialysis patients, factors affecting epoetin dosage and changes in anaemia management over the last 5 years.
Jacobs C; Frei D; Perkins AC
Nephrol Dial Transplant; 2005 May; 20 Suppl 3():iii3-24. PubMed ID: 15824128
[TBL] [Abstract][Full Text] [Related]
10. Is early treatment of anaemia with epoetin-alpha beneficial to pre-dialysis chronic kidney disease patients? Results of a multicentre, open-label, prospective, randomized, comparative group trial.
Macdougall IC; Temple RM; Kwan JT
Nephrol Dial Transplant; 2007 Mar; 22(3):784-93. PubMed ID: 16968726
[TBL] [Abstract][Full Text] [Related]
11. Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly.
Sulowicz W; Locatelli F; Ryckelynck JP; Balla J; Csiky B; Harris K; Ehrhard P; Beyer U;
Clin J Am Soc Nephrol; 2007 Jul; 2(4):637-46. PubMed ID: 17699476
[TBL] [Abstract][Full Text] [Related]
12. Maintenance of elevated versus physiological iron indices in non-anaemic patients with chronic kidney disease: a randomized controlled trial.
McMahon LP; Kent AB; Kerr PG; Healy H; Irish AB; Cooper B; Kark A; Roger SD
Nephrol Dial Transplant; 2010 Mar; 25(3):920-6. PubMed ID: 19906658
[TBL] [Abstract][Full Text] [Related]
13. Intravenous ascorbic acid in hemodialysis patients with functional iron deficiency: a clinical trial.
Giancaspro V; Nuzziello M; Pallotta G; Sacchetti A; Petrarulo F
J Nephrol; 2000; 13(6):444-9. PubMed ID: 11132761
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of once-weekly and once-fortnightly subcutaneous epoetin beta in peritoneal dialysis patients with chronic renal anaemia.
Grzeszczak W; Sulowicz W; Rutkowski B; de Vecchi AF; Scanziani R; Durand PY; Bajo A; Vargemezis V;
Nephrol Dial Transplant; 2005 May; 20(5):936-44. PubMed ID: 15769814
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
[TBL] [Abstract][Full Text] [Related]
16. Clinical benefits of epoetin alfa (Eprex) 10,000 units subcutaneously thrice weekly in Thai cancer patients with anemia receiving chemotherapy.
Voravud N; Sriuranpong V
J Med Assoc Thai; 2005 May; 88(5):607-12. PubMed ID: 16149676
[TBL] [Abstract][Full Text] [Related]
17. Administration of the same dose of epoetin-beta intravenously and subcutaneously to patients with renal anaemia.
Steffensen GK; Stergaard O
Scand J Urol Nephrol; 2011 Dec; 45(6):461-9. PubMed ID: 21736448
[TBL] [Abstract][Full Text] [Related]
18. Randomized trial on the therapeutic equivalence between Eprex and GerEPO in patients on haemodialysis.
Goh BL; Ong LM; Sivanandam S; Lim TO; Morad Z;
Nephrology (Carlton); 2007 Oct; 12(5):431-6. PubMed ID: 17803464
[TBL] [Abstract][Full Text] [Related]
19. [Guidelines for the treatment of anemia in chronic renal failure].
Triolo G;
G Ital Nefrol; 2003; 20 Suppl 24():S61-82. PubMed ID: 14666504
[TBL] [Abstract][Full Text] [Related]
20. Subcutaneous epoetin-alpha every one, two, and three weeks in renal anemia.
Piccoli A; Malagoli A; Komninos G; Pastori G
J Nephrol; 2002; 15(5):565-74. PubMed ID: 12455725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
